PDS Biotechnology (NASDAQ:PDSB) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of PDS Biotechnology (NASDAQ:PDSB) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

Separately, HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of PDS Biotechnology in a research report on Wednesday.

PDS Biotechnology Price Performance

PDS Biotechnology stock opened at $1.75 on Friday. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $79.99 million, a PE ratio of -1.51 and a beta of 1.27. PDS Biotechnology has a 12 month low of $0.85 and a 12 month high of $4.42. The stock has a 50-day moving average price of $1.34 and a two-hundred day moving average price of $1.46.

PDS Biotechnology (NASDAQ:PDSB) last posted its earnings results on Wednesday, May 14th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.04. Analysts expect that PDS Biotechnology will post -1.2 EPS for the current year.

Institutional Investors Weigh In On PDS Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new stake in shares of PDS Biotechnology in the fourth quarter valued at about $26,000. Jane Street Group LLC acquired a new stake in shares of PDS Biotechnology in the fourth quarter valued at about $58,000. Marshall Wace LLP increased its stake in shares of PDS Biotechnology by 38.4% in the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock valued at $64,000 after buying an additional 10,837 shares during the period. Virtu Financial LLC acquired a new stake in shares of PDS Biotechnology in the fourth quarter valued at about $89,000. Finally, Two Sigma Investments LP increased its stake in shares of PDS Biotechnology by 273.5% in the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock valued at $107,000 after buying an additional 48,132 shares during the period. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.